CARVYKTI Achieves 33% Five-Year Progression-Free Survival in Relapsed Multiple Myeloma

New long-term results from the CARTITUDE-1 study, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrate that CARVYKTI® (ciltacabtagene autoleucel), a CAR-T cell therapy for relapsed/refractory multiple myeloma (RRMM), provides durable benefits, with 33% of patients remaining progression-free for five years or more after a single infusion. The median overall survival for the 97 heavily pre-treated patients was 60.7 months, and the safety profile remained favorable with no new adverse events. Additional data from the CARTITUDE-4 trial showed CARVYKTI® improved progression-free survival and overall survival across various high-risk patient subgroups. Experts highlight the potential of CARVYKTI® to offer long-term disease control and possibly transform multiple myeloma treatment from management to cure. Furthermore, early data on next-generation cell therapies targeting other cancers were also presented, underscoring ongoing innovation in cell therapy. These findings mark a significant advancement in treatment options for patients with multiple myeloma.